Avinger Announces Commercial Launch in Australia
December 06, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based...
AngioSoma Launching Holiday Awareness Campaign
November 12, 2018 07:00 ET
|
AngioSoma, Inc.
Heart Health Focused Campaign Set to Kick Off December 1st, 2018 HOUSTON, TX, Nov. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma (OTC: SOAN), a leading biotechnology research and...
Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee
November 10, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
October 25, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
April 13, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015
October 12, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
January 08, 2015 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Biodegradable Stent Safe for Long-Term Treatment of Coronary Artery Disease
April 16, 2012 16:00 ET
|
American Heart Association
Study Highlights:
The first fully biodegradable stent inserted into humans proved safe in a 10-year study.
Major cardiac complication rates were similar to rates of non-biodegradable stents...
Peripheral Artery Disease Undertreated, Understudied in Women
February 15, 2012 16:00 ET
|
American Heart Association
Statement Highlights:
Peripheral artery disease, or PAD, can increase the risk of heart attack or stroke, yet is often unrecognized and untreated in women.
Healthcare providers should...
Awareness of Peripheral Artery Disease Low Among Those With Highest Risk
September 06, 2011 14:30 ET
|
American Heart Association
DALLAS, Sept. 6, 2011 (GLOBE NEWSWIRE) -- Awareness of peripheral artery disease is low among those at greatest risk for developing the condition, according to the American Heart Association.
Only...